MedTrace Logo

Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors

NCT00303732 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2016-03-03

No results posted yet for this study

Summary

RATIONALE: Vatalanib and everolimus may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of vatalanib and everolimus and to see how well they work in treating patients with advanced solid tumors.

Conditions

Interventions

DRUG

RAD001 (everolimus)

DRUG

PTK787 (vatalanib)

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Daniel George, MD

    lead OTHER

Principal Investigators

  • Daniel J. George, MD · Duke Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2010-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00303732 on ClinicalTrials.gov